DE, dissolution efficiency; DP, percent drug dissolved; DSC, differential scanning calorimetry; Me-β-CD, methyl-β-cyclodextrin; SC-CO2, supercritical carbon dioxide; SEM, rpm, revolutions per minute; Scanning electron microscopy; XRPD: X-ray powder diffraction.
Introduction
The water solubility of a drug is a key indicator for the solubility of drug molecules in the intestinal fluids and its contribution to bioavailability. The success of a pharmaceutical formulation relies on how effectively it makes the drug molecules available at the site of absorption. However, poor water solubility and the resulting poor oral bioavailability of most drugs available on the market has long been a problem to pharmaceutical scientists, as the dissolution is quite often the rate-limiting process in the absorption of a drug (Charman and Stella, 1991; Takagi et al., 2006) . The ability to increase the water solubility of a drug is thus very important to enhancing its therapeutic efficacy. Several strategies to improve the water solubility and dissolution rate of poorly soluble drugs have been reported (Gupta et al., 1997; Ambade et al., 2008; Tokumura et al., 2009; Rudrangi et al., 2011; Oh et al., 2011; Bontha et al., 2012; Rudrangi et al., 2015a; Kaialy and Al Shafiee, 2015) , among which is the inclusion complexation with cyclodextrins (Jain and Adeyeye, 2001; Bandi et al., 2004; Cirri et al., 2005; Vega et al., 2013; Rudrangi et al., 2015a; Rudrangi et al., 2015b) .
Cyclodextrins are a family of non-reducing cyclic oligosaccharides composed of (α-1,4)-linked α-D-glucopyranose units. They possess a hydrophobic cavity and a hydrophilic exterior (Kfoury et al., 2015) . The hydrophobic cavity can accommodate a poorly watersoluble drug, whilst the hydrophilic exterior facilitates high water solubility (Rudrangi et al., 2015a) .
Flurbiprofen [2-(2-fluoro-4-biphenylyl) propionic acid] is a potent chiral non-steroidal antiinflammatory drug approved by the Food and Drug Administration for the treatment of rheumatoid arthritis and osteoarthritis (Davies, 1995) . It also has profound analgesic effects and is indicated in the treatment of gingivitis and alveolar bone resorption in periodontitis (Heasman, P.A. et al., 1990) . However, it has poor water solubility (5-13 µg mL -1 ) and 4 dissolution rate (Anderson and Conradi, 1985) , which limits both its therapeutic application and efficacy. Hence, there is a need to enhance the water solubility and dissolution rate of flurbiprofen.
Several formulation strategies have been reported to improve the solubility and dissolution rate of flurbiprofen, such as dry elixir (Kim and Yoon, 1995) , solid dispersion (Habib et al., 1998; Oh et al., 2011) , salt formation (Gupta et al., 1997) , microemulsion (Park et al., 1997; Ambade et al., 2008) , inclusion complex with cyclodextrins (Tokumura et al., 2009; Li et al., 2010) and cycloamyloses (Baek et al., 2011) .
Flurbiprofen has an affinity for different cyclodextrins forming inclusion complexes. The favourable effect of natural β-cyclodextrin (Muraoka et al., 2004; Cirri et al., 2005; Tokumura et al., 2009; Li et al., 2010; Baek et al., 2011) and its derivatives, such as hydroxypropyl-β-cyclodextrin (Govindarajan and Nagarsenker, 2005; Vega et al., 2013) , hydroxyethyl-β-cyclodextrin and methyl-β-cyclodextrin (Cirri et al., 2005) on its pharmaceutical properties has been previously reported. For example, Cirri et al. (2005) reported that flurbiprofen and methyl-β-cyclodextrin (Me-β-CD) complexes prepared in the 1:1 molar ratio using kneading and co-evaporation techniques exhibit higher solubility and dissolution profiles than flurbiprofen alone or in a state of a physical mixture. In spite of their success, the complexes prepared by the co-evaporation and kneading methods required an organic solvent. Organic solvents are potentially hazardous and their presence in the final product (complexes) is highly undesirable and often requires energy-intensive drying steps involving a great deal of time to remove the residual solvent (Al-Marzouqi et al., 2007; AlMarzouqi et al., 2009) . Hence, there is a need to avoid the use of organic solvents in the preparation of drug-cyclodextrin complexes.
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Pharmaceutical scientists relentlessly try to avoid the usage of toxic organic solvents and exchange those to more environmentally friendly alternatives with similar properties. One of those effective alternatives is the use of supercritical fluids. A supercritical fluid is a substance that exists above its critical point, where the phase boundaries diminish. Carbon dioxide is the most commonly employed supercritical fluid because of its low critical parameters. Supercritical carbon dioxide (SC-CO2) has provided an excellent green alternative to harmful organic solvents and the use of SC-CO2 processing technique in the preparation of drug-cyclodextrin complexes has been reported (York, 1999; Kompella and Koushik, 2001; Sunkara and Kompella, 2002; Türk et al., 2007; Lee et al., 2008; Rudrangi et al., 2015a; Rudrangi et al., 2015b) .
The application of supercritical carbon dioxide processing in the preparation of flurbiprofenMe-β-CD complexes has not yet been investigated. Therefore, the aim of this study was to evaluate supercritical fluid technology as a preparative technique for the preparation of flurbiprofen-Me-β-CD inclusion complexes in solid-state. Inclusion complexes were prepared by physical mixing and SC-CO2 processing at various working (temperature and pressure) conditions. The prepared complexes were then characterized by solubility studies, differential scanning calorimetry (DSC), X-ray powder diffraction (XRD), scanning electron microscopy (SEM), practical yield, drug content evaluation and dissolution studies.
Materials and methods

Materials
Flurbiprofen (≥ 98.5%, molecular weight: 244.26 g/mol) and Me-β-CD (average molecular weight: 1310 g/mol, extent of labeling: 1.6-2.0 mol CH3 per unit anhydroglucose) were purchased from Sigma-Aldrich (Gillingham, Dorset, UK 
Supercritical carbon dioxide process
The SC-CO2 process was carried out in the static mode to achieve the inclusion of flurbiprofen in the Me-β-CD. The complexes were prepared using an extraction apparatus supplied by Thar Process Inc., USA as described in detail elsewhere (Rudrangi et al., 2015b) .. 
Analysis of the prepared binary mixtures
Having prepared these model complexes by supercritical carbon dioxide processing, the next aim is to compare the physical properties with those of complexes prepared using physical mixing.
2.3.1. Solubility studies Saturation solubility of flurbiprofen was measured in triplicate by adding excess amounts of the drug to 10 mL of deionised water in sealed glass containers. The solutions were agitated for 72 hours at 25 °C. The solutions were then filtered (0.45 µm filter pore size) and assayed for drug concentration by ultra-violet spectroscopy (Cary 100 UV-vis, Agilent Technologies, USA) after dilution.
Phase solubility diagram was obtained according to the method reported by Higuchi and Connors (1965) . Samples were prepared by adding excess flurbiprofen (in an amount above its solubility), to a 10 mL deionised water containing successively increasing concentrations The degree of crystallinity (% crystallinity) of the flurbiprofen-Me-β-CD complex systems was determined using the amorphous subtraction method as reported previously (Rudrangi et al., 2015a) .
Scanning electron microscopy (SEM) analysis
The surface morphology of flurbiprofen, Me-β-CD and the flurbiprofen-Me-β-CD complex systems was examined by means of Hitachi SU-8030 scanning electron microscope (Tokyo, Japan). The powder samples were securely fixed on an aluminium stub using double-sided adhesive tape and then were made electrically conductive by coating in vacuum with a thin layer of chromium (~300 Å) at 30 W for 30 seconds. The photomicrographs were taken at an excitation voltage of 1.0 kV and a magnification of ×350.
Practical yield
The efficiency of a processing method used for the preparation of inclusion complexes can be measured by determining the practical yield of the binary systems. The percentage practical yield of the binary systems was determined using the following equation: 
In vitro dissolution studies
In vitro dissolution studies of flurbiprofen from all drug-carrier binary systems, and for flurbiprofen alone, were conducted in triplicate using USP Type II paddle method (Hanson G2 Vision ® Classic 6, Chatsworth, CA) with deionised water as the dissolution medium. The samples, corresponding to 1000 mg of flurbiprofen were dispersed into 900 mL of the dissolution media maintained at 25 + 0.5 °C and stirred at 100 rpm. Aliquots (5 mL) were withdrawn and filtered (0.45 µm filter pore size) at the specified time intervals (2, 5, 10, 20, 30 and 60 min) and the drug concentration was determined by UV spectroscopy at a λmax of 246 nm. The same volume of fresh medium was added to the vessel and the correction for the cumulative dilution was calculated. The parameters used to characterize the dissolution curves were the percentage of flurbiprofen dissolved at 30 min, and the dissolution efficiency at 30 and 60 min. The dissolution efficiency was calculated according to Khan (1975) .
DE30min was calculated from the area under the dissolution curve at 30 min and expressed as a percentage of the area of the rectangle described by 100% dissolution in the same time of the total amount added.
Molecular docking studies
Molecular docking studies were conducted to study the possibility of molecular arrangement of inclusion complexes between flurbiprofen and Me-β-CD. Molecular docking studies of flurbiprofen into Me-β-CD were conducted using Glide (grid-based ligand docking) application implemented in the Maestro 9.3 software package (Schrodinger, LLC, New York, USA, 2012) as reported earlier (Rudrangi et al., 2015b) . Docked flurbiprofen and Me-β-CD complexes were visualised and molecular surface complex pictures were generated using Maestro. 
Results and discussions
Solubility studies
Solid-state analyses
The DSC traces of the unprocessed flurbiprofen and SC-CO2 processed flurbiprofen (Fig. 2a) showed sharp melting endotherms at 118.26 °C and 118.27 °C, respectively, confirming that SC-CO2 process has not altered the crystallinity of the drug, as further substantiated by XRPD analysis (Fig. 2b) . Similar results were reported by Rudrangi et al. (2015a and b) for indomethacin and olanzapine when processed with SC-CO2. 
Scanning electron microscopy analysis
From SEM analysis, unprocessed pure flurbiprofen (Fig. 4a ) appeared as columnar crystals (8-40 µm) with a smooth surface. Pure Me-β-CD appeared as perforated hollow spheres in 15 the size range of 10-90 µm (Fig. 4b) . The physical mixture product showed a mixture of small columnar crystals (10-15 µm) and broken hollow spheres (50-75 µm) (Fig. 4c) . 
Practical yield
The percentage practical yield of all the binary mixtures is tabulated in Table 1 . It was observed that all the binary mixtures prepared by SC-CO2 processing resulted in the loss of 17 mass of the complexes to some extent. The practical yields of the binary mixtures prepared by SC-CO2 processing were above 96% (w/w). Table 1 . Percentage practical yield of flurbiprofen-Me-β-CD binary systems.
Evaluation of the flurbiprofen content
The percentage drug content the binary mixtures ranged from 94.59 ± 0.31% to 97.88 ± 0.18%, which is within the acceptable range (85-115%) provided in the United States Pharmacopoeia 29 (USP 29, 2006) . Table 2 . Drug content in flurbiprofen-Me-β-CD binary systems (mean ± SD, n=3).
Method Practical yield (%)
Physical mixing The percent flurbiprofen dissolved at 30 min (DP30min) and the dissolution efficiency at 30 min (DE30 min) is presented in Table 3 . The amount of flurbiprofen released from drug alone was very low with 1.11 ± 0.09% dissolving at the end of 60 min, whereas the binary mixture obtained by physical mixing exhibited a significant increase in the dissolution with 72.47 ± 3.23% of flurbiprofen dissolved at the end of 30 min.
It is also evident from the results (Fig. 7 and Table 3 ) that the degree of the improvement in the dissolution rate is dependent on not only the method of preparation but also the processing conditions used for the preparation of complexes. All the SC-CO2 processed systems exhibited higher apparent drug dissolution than the physical mixture systems;
however, considerable differences were observed in the degree of enhancement. The instantaneous dissolution properties offered by all the binary mixtures are attributable to the improvement in drug wettability due to the high aqueous solubility (greater than 2000 mg mL -1 as reported by Banchero et al., 2013) and the superior complexing properties of Me-β-CD (Cirri et al., 2005) . The single best pose of flurbiprofen docked in the cavity of Me-β-CD is presented in Fig. 6 . 
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Computational molecular docking studies of indomethacin and olanzapine with Me-β-CD were carried out by Rudrangi and co-workers using the Glide application. The binding affinity (GLIDE energy), van der Waals energy and docking score for inclusion of indomethacin in Me-β-CD were 27.880 kcal mol -1 , -28.941 kcal mol -1 and -4.882 kcal mol -1 , respectively (Rudrangi et al., 2015a) , while the binding affinity, Van der Waals energy and docking score for inclusion of olanzapine in Me-β-CD were -24.13 kcal mol -1 , -21.57 kcal mol -1 and -3.09 kcal mol -1 , respectively (Rudrangi et al., 2015b) .
Conclusions
A novel solid inclusion method for the complexation flurbiprofen into methyl-β-cyclodextrin using supercritical carbon dioxide carrier was shown. The possibility of flurbiprofen-methyl-β-cyclodextrin interactions of different efficiencies in the solid-state was demonstrated.
Products obtained by the supercritical carbon dioxide processing exhibited the highest apparent drug dissolution followed by the physical mixture and the drug alone. All the products processed by SC-CO2 at 45 °C offered more than 80% drug release within the first 10 min irrespective of the pressure employed. Both the temperature and pressure showed a positive influence on the formation of the inclusion complexes in the solid-state, with temperature playing even a higher role. The method proposed involves no toxic solvent residues, thus the products obtained provide minimal side effects in humans, compared to those obtained by other techniques that require the use of organic solvents. The preliminary data suggests that the complexation of flurbiprofen with methyl-β-cyclodextrin will lead to better therapeutic efficacy.
